<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; per</title>
	<atom:link href="http://www.tapanray.in/tag/per/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Price Control in India: A Fresh Advocacy With Blunt Edges</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/#comments</comments>
		<pubDate>Mon, 07 Sep 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[blunt]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[edges]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pharmasofttech]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yeh dil maange more]]></category>
		<category><![CDATA[“Assessing the Impact of Price Control Measures on Access to Medicines in India”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7017</guid>
		<description><![CDATA[It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Aggressive New Drug Pricing Trend: What It Means To India?</title>
		<link>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-aggressive-new-drug-pricing-trend-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 27 Oct 2014 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[aggressive]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmony]]></category>
		<category><![CDATA[HCV. Sovaldi]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Script]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6134</guid>
		<description><![CDATA[A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue &#8230; <a href="http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs’ Pricing: Apprehensive Voices Could Turn into a Self-Defeating Prophecy</title>
		<link>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy</link>
		<comments>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/#comments</comments>
		<pubDate>Mon, 04 Mar 2013 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[apprehensive]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CIPI]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[FICCI]]></category>
		<category><![CDATA[FOPE]]></category>
		<category><![CDATA[gandhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[IDMA]]></category>
		<category><![CDATA[IIT]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[Kharagpur]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NewZealand]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[PCPD]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[rajiv]]></category>
		<category><![CDATA[ratio]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2016</guid>
		<description><![CDATA[On February 21, 2013, the Department of Pharmaceuticals in a communication to the stakeholders announced that the committee to examine the issues of ‘Price Negotiations for Patented Drugs’ has since submitted its report to the Department. Simultaneously the stakeholders were &#8230; <a href="http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
